OS Therapies Inc SEC filings OSTX
OS Therapies Inc has 243 filings in SEC EDGAR's recent list, going back to Dec 5, 2019. Its latest annual report, Form ARS, was filed on Jul 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 19, 2026 (material agreement, unregistered share sale, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 4 | Insider transaction | Oct 30, 2026 | Oct 22, 2026 |
| 4 | Insider transaction | Oct 30, 2026 | Oct 22, 2026 |
| 4 | Insider transaction | Oct 30, 2026 | Oct 22, 2026 |
| 4 | Insider transaction | Oct 30, 2026 | Oct 22, 2026 |
| 4 | Insider transaction | Oct 30, 2026 | Oct 22, 2026 |
| 4 | Insider transaction | Oct 30, 2026 | Oct 22, 2026 |
| 4 | Insider transaction | Oct 30, 2026 | Oct 22, 2026 |
| 4 | Insider transaction | Oct 30, 2026 | Oct 22, 2026 |
| 4 | Insider transaction | Oct 30, 2026 | Oct 22, 2026 |
| 3 | Initial insider ownership | Oct 5, 2026 | Sep 29, 2026 |
| 3 | Initial insider ownership | Oct 5, 2026 | Sep 29, 2026 |
| 3 | Initial insider ownership | Jul 23, 2026 | Jul 1, 2026 |
| 5/A | Filing | May 15, 2026 | Dec 31, 2024 |
| 4 | Insider transaction | Feb 13, 2026 | Jan 22, 2026 |
| 4 | Insider transaction | Feb 13, 2026 | Jan 22, 2026 |
| 4 | Insider transaction | Feb 13, 2026 | Jan 22, 2026 |
| 4 | Insider transaction | Feb 13, 2026 | Jan 22, 2026 |
| 4 | Insider transaction | Feb 13, 2026 | Jan 22, 2026 |
| 4 | Insider transaction | Feb 13, 2026 | Jan 22, 2026 |
| 4 | Insider transaction | Feb 13, 2026 | Jan 22, 2026 |
| 4 | Insider transaction | Feb 13, 2026 | Jan 22, 2026 |
| 4/A | Filing | Feb 13, 2026 | Oct 21, 2025 |
| 4 | Insider transaction | Dec 19, 2025 | Oct 21, 2025 |
| 4 | Insider transaction | Dec 19, 2025 | Oct 21, 2025 |
| 4 | Insider transaction | Dec 19, 2025 | Oct 21, 2025 |
| 4 | Insider transaction | Dec 19, 2025 | Oct 21, 2025 |
| 4 | Insider transaction | Dec 19, 2025 | Oct 21, 2025 |
| 4 | Insider transaction | Dec 19, 2025 | Oct 21, 2025 |
| 4 | Insider transaction | Dec 19, 2025 | Oct 21, 2025 |
| 4 | Insider transaction | Dec 19, 2025 | Oct 21, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Aug 18, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 13, 2025 | — |
| 4 | Insider transaction | May 9, 2025 | May 9, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | May 9, 2025 | — |
| 4 | Insider transaction | May 9, 2025 | May 7, 2025 |
| 144 | Notice of proposed sale | May 7, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Apr 16, 2025 | — |
| 4 | Insider transaction | Apr 11, 2025 | Apr 9, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Mar 12, 2025 | — |
| 4 | Insider transaction | Feb 28, 2025 | Feb 28, 2025 |
| 4 | Insider transaction | Feb 28, 2025 | Feb 27, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Feb 28, 2025 | — |
| 3/A | Filing | Feb 26, 2025 | Jul 31, 2024 |
| 4 | Insider transaction | Feb 18, 2025 | Feb 14, 2025 |
| 5 | Annual insider ownership | Feb 14, 2025 | Dec 31, 2024 |
| 5 | Annual insider ownership | Feb 14, 2025 | Dec 31, 2024 |
| 5 | Annual insider ownership | Feb 14, 2025 | Dec 31, 2024 |
| 5 | Annual insider ownership | Feb 14, 2025 | Dec 31, 2024 |
| 5 | Annual insider ownership | Feb 14, 2025 | Dec 31, 2024 |
| 5 | Annual insider ownership | Feb 14, 2025 | Dec 31, 2024 |
| 5 | Annual insider ownership | Feb 14, 2025 | Dec 31, 2024 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 12, 2025 | — |
| 3 | Initial insider ownership | Feb 6, 2025 | Jan 28, 2025 |
| SCHEDULE 13D | Ownership over 5% (active) | Jan 17, 2025 | — |
| 4 | Insider transaction | Jan 17, 2025 | Jan 15, 2025 |
| 4 | Insider transaction | Jan 14, 2025 | Aug 2, 2024 |
| 3 | Initial insider ownership | Jan 14, 2025 | Jul 31, 2024 |
| 3 | Initial insider ownership | Oct 29, 2024 | Oct 28, 2024 |
| 3 | Initial insider ownership | Oct 29, 2024 | Oct 28, 2024 |
| SC 13G | Ownership over 5% (passive) | Aug 28, 2024 | — |
| 4 | Insider transaction | Aug 6, 2024 | Aug 2, 2024 |
| 4 | Insider transaction | Aug 6, 2024 | Aug 2, 2024 |
| 3 | Initial insider ownership | Aug 1, 2024 | Jul 31, 2024 |
| 3 | Initial insider ownership | Aug 1, 2024 | Jul 31, 2024 |
| 3 | Initial insider ownership | Aug 1, 2024 | Jul 31, 2024 |
| 3 | Initial insider ownership | Aug 1, 2024 | Jul 31, 2024 |
| 3 | Initial insider ownership | Aug 1, 2024 | Jul 31, 2024 |
| 3 | Initial insider ownership | Aug 1, 2024 | Jul 31, 2024 |
| 3 | Initial insider ownership | Aug 1, 2024 | Jul 31, 2024 |
Showing 69 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OSTX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Rockville, MD
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1795091
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.